Biomarker-confirmed endpoints for the disease-modifying pipeline
Prodromal Alzheimer's disease represents the biomarker-confirmed stage where amyloid and tau pathology are present alongside early cognitive symptoms. This is the primary target for the current wave of disease-modifying therapies, and the field needs endpoints that can detect meaningful cognitive change over trial-feasible timeframes.
The Prodromal AD Endpoint Challenge
Recent anti-amyloid approvals have validated the target, but endpoint sensitivity remains a bottleneck. CDR-SB and ADAS-Cog detect group-level differences in large trials (N=1,000+) but require 18-month durations and still produce modest effect sizes. For the next generation of therapies targeting tau, neuroinflammation, or synaptic repair, smaller and shorter trials are needed. That requires more sensitive endpoints.
Why Consolidation Matters for Prodromal AD
Memory consolidation depends on intact hippocampal function and sleep architecture, both of which are disrupted in prodromal AD. Amyloid plaques impair slow-wave sleep, tau pathology degrades hippocampal circuits, and the resulting consolidation failure produces the episodic memory loss that defines the clinical syndrome. FaceWise measures this process directly, providing a closer readout of the pathophysiology that therapies target.
Published Evidence
Research supporting consolidation-based endpoints for prodromal alzheimer's disease assessment.
Amyloid Disrupts Sleep-Dependent Consolidation
Amyloid-beta accumulation in medial prefrontal cortex reduces slow-wave activity during NREM sleep, impairing hippocampal replay and overnight memory consolidation. This disruption is proportional to amyloid burden.
Mander BA, et al. Nature Neuroscience, 2015. DOI: 10.1038/nn.4035
Tau Pathology and Hippocampal Memory
Tau neurofibrillary tangles concentrate in medial temporal lobe structures critical for memory encoding and consolidation. FNAME performance correlates with tau PET signal in entorhinal cortex.
Published tau PET and cognitive correlation studies
Consolidation as a Treatment-Sensitive Outcome
If a disease-modifying therapy preserves hippocampal function or improves sleep architecture, consolidation-based endpoints should detect the effect before broad cognitive composites register change.
Theoretical framework supported by published consolidation-pathology correlations
Trial Applications
Clinical trial contexts where FaceWise consolidation endpoints add value for prodromal alzheimer's disease programs.
Ready to discuss prodromal alzheimer's disease endpoints?
Schedule a consultation to explore how FaceWise consolidation endpoints can strengthen your prodromal alzheimer's disease clinical program.